The effect of propolis plus Hyoscyamus niger L. methanolic extract on clinical symptoms in patients with acute respiratory syndrome suspected to COVID‐19: A clinical trial. (15th April 2021)

• Record Type: Journal Article
• Authors: Kosari, Morteza; Noureddini, Mehdi; Khamechi, Seyed Peyman; Najafi, Ahmad; Ghaderi, Amir; Sehat, Mojtaba; Banafshe, Hamid Reza
• Is Part Of: Phytotherapy research. Volume 35:Number 7(2021)
• Page Start: 4000
• Page End: 4006
• Publication Date: 2021-04-15
• Subjects: COVID‐19 -- Hyoscyamus niger L. -- propolis; Materia medica, Vegetable -- Periodicals; Botany, Medical -- Periodicals; Medicinal plants -- Periodicals; Plant Extracts -- therapeutic use -- Periodicals; Plants, Medicinal -- Periodicals; 581.634
• DOI: 10.1002/ptr.7116
• Languages: English
• ISSNs: 0951-418X

Abstract

Abstract : The outbreak of Coronavirus disease 2019 (COVID‐19) has caused a global health crisis. Nevertheless, no antiviral treatment has yet been proven effective for treating COVID‐19 and symptomatic supportive cares have been the most common treatment. Therefore, the present study was designed to evaluate the effects of propolis and Hyoscyamus niger L. extract in patients with COVID‐19. This randomized clinical trial was conducted on 50 cases referred to Akhavan and Sepehri Clinics, Kashan university of medical sciences, Iran. Subjects were divided into two groups (intervention and placebo). This syrup (containing 1.6 mg of methanolic extract along with 450 mg of propolis per 10 mL) was administered three times a day to each patient for 6 days. The clinical symptoms of COVID‐19 such as: dry cough, shortness of breath, sore throat, chest pain, fever, dizziness, headache, abdominal pain, and diarrhea were reduced with propolis plus Hyoscyamus niger L. extract than the placebo group. However, the administration of syrup was not effective in the control of nausea and vomiting. In conclusion, syrup containing propolis and Hyoscyamus niger L. extract had beneficial effects in ameliorating the signs and symptoms of COVID‐19 disease, in comparison with placebo groups.